Compare · DFTX vs MEHA
DFTX vs MEHA
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Functional Brands Inc. (MEHA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MEHA operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $5.14B, about 6392.5x MEHA ($803,570).
- Over the past year, DFTX is up 290.8% and MEHA is down 99.3% - DFTX leads by 390.1 points.
- DFTX has been more active in the news (7 items in the past 4 weeks vs 2 for MEHA).
- DFTX has more recent analyst coverage (7 ratings vs 0 for MEHA).
PerformanceDFTX+231.60%MEHA-99.30%
2025-11-05+0.00%2026-09-08
- Company
- Definium Therapeutics Inc.
- Functional Brands Inc.
- Price
- $38.20+0.32%
- $0.02-53.98%
- Market cap
- $5.14B
- $803,570
- 1M return
- -17.19%
- +0.00%
- 1Y return
- +290.79%
- -99.30%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 2
- Recent ratings
- 7
- 0
Latest DFTX
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
- Chief Executive Officer Barrow Robert was granted 40,000 shares and sold $721,733 worth of shares (19,023 units at $37.94) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 1,494,640 units (SEC Form 4) (tax withholding)
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
Latest MEHA
- Functional Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Functional Brands Announces Second Quarter 2026 Financial Results
- SEC Form 25-NSE filed by Functional Brands Inc.
- Functional Brands Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- Functional Brands Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Functional Brands Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Functional Brands Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Functional Brands Inc.
- SEC Form DEFA14A filed by Functional Brands Inc.
- Amendment: Functional Brands Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits